{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:03:38Z","timestamp":1760385818539,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40262-020-00943-6","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T18:02:37Z","timestamp":1600538557000},"page":"319-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-8002","authenticated-orcid":false,"given":"Dinko","family":"Reki\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-2967","authenticated-orcid":false,"given":"Jacob","family":"Leander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,19]]},"reference":[{"key":"943_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/14656566.2017.1351945","volume":"18","author":"T Pascart","year":"2017","unstructured":"Pascart T, Richette P. Current and future therapies for gout. Expert Opin Pharmacother. 2017;18:1201\u201311. https:\/\/doi.org\/10.1080\/14656566.2017.1351945.","journal-title":"Expert Opin Pharmacother"},{"key":"943_CR2","unstructured":"Takeda Pharmaceuticals USA. Uloric (febuxostat) [package insert]. US Food and Drug Administration; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021856s013lbl.pdf. Accessed 9 Sept 2020."},{"key":"943_CR3","unstructured":"Menarini Group. Adenuric (febuxostat) [package leaflet]. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adenuric-epar-product-information_en.pdf. Accessed 9 Sept 2020."},{"key":"943_CR4","unstructured":"Teijin Pharm. Feburic (febuxostat) [package leaflet]. 2020. https:\/\/www.pins.japic.or.jp\/pdf\/newPINS\/00059341.pdf. Accessed 9 Sept 2020."},{"key":"943_CR5","doi-asserted-by":"crossref","unstructured":"Pisano A, Cernaro V, Gembillo G, D\u2019Arrigo G, Buemi M, Bolignano D. Xanthine oxidase inhibitors for improving renal function in chronic kidney disease patients: an updated systematic review and meta-analysis. Int J Mol Sci. 2017;18:2283. http:\/\/www.mdpi.com\/1422-0067\/18\/11\/2283.","DOI":"10.3390\/ijms18112283"},{"key":"943_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40262-016-0466-4","volume":"56","author":"B Kamel","year":"2017","unstructured":"Kamel B, Graham GG, Williams KM, Pile KD, Day RO. Clinical pharmacokinetics and pharmacodynamics of febuxostat. Clin Pharmacokinet. 2017;56:459\u201375.","journal-title":"Clin Pharmacokinet"},{"key":"943_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/cpdd.463","volume":"8","author":"J Hall","year":"2019","unstructured":"Hall J, Gillen M, Yang X, Shen Z. Pharmacokinetics, pharmacodynamics, and tolerability of concomitant administration of verinurad and febuxostat in healthy male volunteers. Clin Pharmacol Drug Dev. 2019;8:179\u201387.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"943_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2017-000584","volume":"4","author":"R Fleischmann","year":"2018","unstructured":"Fleischmann R, Winkle P, Hall J, Valdez S, Liu S, Yan X, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open. 2018;4:1\u20138.","journal-title":"RMD Open"},{"key":"943_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/rheumatology\/key100","volume":"57","author":"M Shiramoto","year":"2018","unstructured":"Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, et al. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology. 2018;57:1602\u201310.","journal-title":"Rheumatology"},{"key":"943_CR10","unstructured":"USA Food and Drug Administration. Uloric (febuxostat). Clinical pharmacology review. NDA 21-856. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/021856s000_ClinPharmR_P3.pdf. Accessed 9 Sept 2020."},{"key":"943_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1208\/ps040427","volume":"4","author":"U W\u00e4hlby","year":"2002","unstructured":"W\u00e4hlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic\u2013pharmacodynamic analysis. AAPS Pharm Sci. 2002;4:68\u201379.","journal-title":"AAPS Pharm Sci."},{"key":"943_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"THT Nguyen","year":"2017","unstructured":"Nguyen THT, Mouksassi M, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2017;6:87\u2013109. https:\/\/doi.org\/10.1002\/psp4.12161.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"943_CR13","unstructured":"US Food and Drug Administration. Guidance for industry population pharmacokinetics. 2019. https:\/\/www.fda.gov\/media\/128793\/download. Accessed 9 Sept 2020."},{"key":"943_CR14","unstructured":"Holford NHG. The visual predictive check: superiority to standard diagnostic (Rorschach) plots. Population Approach Group European Meeting. 2005. https:\/\/www.page-meeting.org\/?abstract5738. Accessed 9 Sept 2020."},{"key":"943_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"},{"key":"943_CR16","volume-title":"NONMEM users guides (1989\u20132009)","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM users guides (1989\u20132009). Ellicott City: ICON Development Solutions; 2009."},{"key":"943_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/BF01060053","volume":"8","author":"LB Sheiner","year":"1980","unstructured":"Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8:553\u201371.","journal-title":"J Pharmacokinet Biopharm."},{"key":"943_CR18","unstructured":"Sahota T. NMproject: script based NONMEM execution with shiny interface. 2020. https:\/\/www.github.com\/tsahota\/NMproject. Accessed 9 Sept 2020."},{"key":"943_CR19","unstructured":"\u00c5strand M. nonmem2R: [oading NONMEM output files with functions for visual predictive checks (VPC) and goodness of fit (GOF) plots. 2019. https:\/\/cran.r-project.org\/package=nonmem2R. Accessed 9 Sept 2020."},{"key":"943_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Progr Biomed. 2004;75:85\u201394.","journal-title":"Comput Methods Progr Biomed"},{"key":"943_CR21","unstructured":"R Core team. R: a language and environment for statistical computing. Vienna, Austria. 2020. https:\/\/www.r-project.org\/. Accessed 9 Sept 2020."},{"key":"943_CR22","doi-asserted-by":"crossref","unstructured":"Baron, T K. mrgsolve: simulate from ODE-based models. R package. 2018. https:\/\/www.cran.r-project.org\/package=mrgsolve. Accessed 9 Sept 2020.","DOI":"10.32614\/CRAN.package.mrgsolve"},{"key":"943_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"943_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369.","journal-title":"AAPS J"},{"key":"943_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/BF01061464","volume":"20","author":"NHG Holford","year":"1992","unstructured":"Holford NHG, Ambros RJ, Stoeckel K. Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm. 1992;20:421\u201342.","journal-title":"J Pharmacokinet Biopharm"},{"key":"943_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/9780470087978.ch13","volume-title":"Pharmacometrics: the science of quantitative pharmacology","author":"O P\u00e9tricoul","year":"2007","unstructured":"P\u00e9tricoul O, Cosson V, Fuseau E, Marchand M. Population models for drug absorption and enterohepatic recycling. In: Ette EI, Williams PJ, editors. Pharmacometrics: the science of quantitative pharmacology. Hoboken, NJ: Wiley; 2007. p. 345\u201382."},{"key":"943_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","volume":"68","author":"JK Mukonzo","year":"2009","unstructured":"Mukonzo JK, R\u00f6shammar D, Waako P, Andersson M, Fukasawa T, Milani L, et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009;68:690\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"943_CR28","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1021\/cg400583z","volume":"13","author":"D Maddileti","year":"2013","unstructured":"Maddileti D, Jayabun SK, Nangia A. Soluble cocrystals of the xanthine oxidase inhibitor febuxostat. Cryst Growth Des. 2013;13(7):3188\u20133196.","journal-title":"Cryst Growth Des."},{"key":"943_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0091270010365549","volume":"51","author":"BA Grabowski","year":"2011","unstructured":"Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharmacol. 2011;51:189\u2013201.","journal-title":"J Clin Pharmacol"},{"key":"943_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/cts.12641","volume":"12","author":"YK Lyauk","year":"2019","unstructured":"Lyauk YK, Jonker DM, Lund TM. Dose finding in the clinical development of 60 US Food and Drug Administration-approved drugs compared with learning vs. confirming recommendations. Clin Transl Sci. 2019;12:481\u20139.","journal-title":"Clin Transl Sci."},{"key":"943_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.dmpk.2016.08.003","volume":"32","author":"M Lin","year":"2017","unstructured":"Lin M, Liu J, Zhou H, Wu M, Lv D, Huang Y, et al. Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2017;32:77\u201384. https:\/\/doi.org\/10.1016\/j.dmpk.2016.08.003.","journal-title":"Drug Metab Pharmacokinet"},{"key":"943_CR32","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s10038-019-0677-2","volume":"64","author":"K Hikino","year":"2019","unstructured":"Hikino K, Ozeki T, Koido M, Terao C, Kamatani Y, Murakami Y, et al. Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project. J Hum Genet. 2019;64:1195\u2013202.","journal-title":"J Hum Genet"},{"key":"943_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3892\/etm.2013.1414","volume":"7","author":"M Zhang","year":"2014","unstructured":"Zhang M, Di X, Xu L, Xu J, Yang Y, Jiang N, et al. Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. Exp Ther Med. 2014;7:393\u20136.","journal-title":"Exp Ther Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00943-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00943-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00943-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:44:47Z","timestamp":1723614287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00943-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,19]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00943-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2020,9,19]]},"assertion":[{"value":"3 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dinko Reki\u0107, Susanne Johansson, and Jacob Leander are employed by AstraZeneca and may own stock or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies were conducted in accordance with the US Code of Federal Regulations, Good Clinical Practice, 21 CFR Parts 50, 56, and 312, the ethical principles set forth in the Declaration of Helsinki, the International Conference on Harmonization harmonized tripartite guideline regarding Good Clinical Practice (E6 Consolidated Guidance, April 1996), and the ethical requirements referred to in the European Union directive 2001\/20\/EC. The study protocols were approved by the institutional review boards or ethics committees of the study sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent to participate was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent for publication was obtained from all individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data sets analyzed during the current study are available from AstraZeneca on reasonable request via the data request portal:.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The model code can be requested from the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"DR designed and performed the research and drafted the manuscript. JL designed and performed the researched and edited the manuscript. SJ designed the research and edited the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}